Factors affecting young people's preferences for emerging technologies for chlamydia testing and treatment : a discrete choice experiment in England by Eaton, Susan Elizabeth et al.
  
 
 
 
warwick.ac.uk/lib-publications 
 
 
 
 
 
Original citation: 
Eaton, Sue, Biggerstaff, Deborah, Pink, Joshua, Petrou, Stavros, Osipenko, Leeza, Gibbs, Jo, 
Estcourt, Claudia, Sadiq, Tariq and Szczepura, Ala (2016) Factors affecting young people's 
preferences for emerging technologies for chlamydia testing and treatment : a discrete 
choice experiment in England. In: Public Health Science 2016, Cardiff, UK, 25 Nov 2016. 
Published in: The Lancet, 388 (Supplement 2). S44. 
 
Permanent WRAP URL: 
http://wrap.warwick.ac.uk/81250    
 
Copyright and reuse: 
The Warwick Research Archive Portal (WRAP) makes this work by researchers of the 
University of Warwick available open access under the following conditions.  Copyright © 
and all moral rights to the version of the paper presented here belong to the individual 
author(s) and/or other copyright owners.  To the extent reasonable and practicable the 
material made available in WRAP has been checked for eligibility before being made 
available. 
 
Copies of full items can be used for personal research or study, educational, or not-for-profit 
purposes without prior permission or charge.  Provided that the authors, title and full 
bibliographic details are credited, a hyperlink and/or URL is given for the original metadata 
page and the content is not changed in any way. 
 
Publisher’s statement: 
© 2016, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-
NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ 
 
A note on versions: 
The version presented here may differ from the published version or, version of record, if 
you wish to cite this item you are advised to consult the publisher’s version.  Please see the 
‘permanent WRAP url’ above for details on accessing the published version and note that 
access may require a subscription. 
 
For more information, please contact the WRAP Team at: wrap@warwick.ac.uk 
 
Conference papers for WRAP submitted by Dr Deborah Biggerstaff  
Warwick Medical School, August 2016 
D.L.Biggerstaff@warwick.ac.uk 
 
1) Paper accepted for The Lancet Public Health conference, September, 2016 
 
Title: A discrete choice experiment involving 1,230 young people across England to identify factors 
that influence young people’s preferences for emerging technologies for Chlamydia testing and 
treatment. 
 
Authors:  
Sue Eaton, MSc, Warwick Medical School, University of Warwick, Coventry, UK 
Dr Deborah Biggerstaff, PhD, Warwick Medical School, University of Warwick, Coventry, UK. 
Dr Joshua Pink, PhD, National Institute for Health and Care Excellence, Guidelines Group, 
Manchester, UK. 
Prof Stavros Petrou, Warwick Medical School, University of Warwick, Coventry, UK. 
Dr Leeza Osipenko, PhD, National Institute for Health and Care Excellence, Scientific Advice, London. 
Dr Jo Gibbs, PhD, Research Department of Infection & Population Health, University College London, 
London, UK. 
Prof Claudia S Estcourt, FRCP, Barts and the London School of Medicine & Dentistry, Queen Mary 
University of London, London, UK. 
Dr S Tariq Sadiq FRCP, Institute for Infection and Immunity, St George’s, University of London, 
London, UK. 
Prof Ala Szczepura, D Phil, Faculty of Health & Life Sciences, Coventry University, UK. 
 
Background: 
Technological advances offer opportunities to redesign existing chlamydia screening/testing and 
treatment pathways. The potential exists to improve screening uptake (current range 11%-49%) and 
the proportion of positives successfully treated (range 56%-100%). Innovations underway include 
self-tests networked through mobile phones, which could be combined with online clinical care and 
other non-face-to-face care pathways. Evidence of young people’s preferences should be key to 
informing optimal service re-design.  
 
Aim: To quantify factors influencing young people’s preferences for emerging Chlamydia testing and 
treatment pathway options.  
 Methods: 
Discrete choice experiment (DCE). Methods used to select attributes and levels included (i) a 
systematic literature review of stated preference studies for STI testing and treatment published 
prior to 31 December 2015. Included studies were published in English, included one or more aspect 
of mainstream STI testing and treatment for any STI, undertaken in an OECD high income country. 
Key search terms included stated preference, stated choice, DCE, contingent valuation, and conjoint 
analysis. (ii) four focus groups  using staged recruitment to include spread in age range (16-24 years) 
and other demographic characteristics; (iii) four expert groups including clinicians and researchers. 
The draft questionnaire tested in a pilot (n=9). The final questionnaire (including 25 pairwise choices 
with opt-out) was completed online by a national panel of 16-24 year olds across England 
(YouthSight). Analysis used multinomial logit models and included validity checks.  
 
Findings: 
1,230 respondents (response rate 73%). The strongest attribute influencing preferences was 
Chlamydia test accuracy (OR 3.24, 95% CI 3.13 – 3.36), followed by time to result (OR 1.81, 95% CI 
1.71-1.91). Respondents showed a preference for remote Chlamydia testing options (self-testing, 
self-sampling and postal testing) over attendance at a testing location. A general preference for 
online (OR 1.21, 95% CI 1.15-1.28) versus traditional GP (OR 1.18 (95% CI 1.12-1.24)/pharmacy (OR 
1.15, 95% CI 1.10-1.22)/clinic services (OR 1) was observed for accessing treatment.  Little difference 
observed between face-to-face (OR 1), telephone (OR 0.95, 95% CI 0.90-1), instant messaging (OR 
1.03, 95% CI 0.98-1.07) or email (OR 1.05, 95% CI 1-1.10) methods of access. No significant 
difference in preferences for antibiotic provision e.g. collection from pharmacy (OR 1.07, 95% CI 
1.02-1.13) versus postal delivery (home OR 1.01, 95% CI 0.96-1.06, collection point OR 1.03, 95% CI 
0.98-1.08). 
 
Interpretation: 
This DCE is the first to systematically identify attributes of chlamydia testing and treatment 
important to young people using primary research and then survey a national pre-defined sample to 
quantify preferences. DCE coefficients can help estimate uptake probabilities for re-designed 
chlamydia pathways. Although this DCE was conducted using an online population, which may limit 
generalizabiity to other populations, findings could assist technology developers, policy makers, 
commissioners and service providers to optimise the adoption of emerging technologies and service 
re-design. 
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